In the last six months, the pharmaceutical industry has seen three acquisitions: Pfizer eats Wyeth, Merck eats Schering-Plough, and Roche eats Genentech. Whether these purchases are an answer to the global economic crisis or an answer to the decline in the pipeline many pharmas have been suffering these years is something open for discussion. For us, the important question is, are these movements really the end of an era?

Chemical Process Research and Development in the 21st Century: Challenges, Strategies, and Solutions from a Pharmaceutical Industry Perspective
Acc. Chem. Res. 2009, 42 (5), pp 671–680.
See: 10.1021/ar800257v